SPOTLIGHT -
The Week in Review: April 15-19
Here are highlights from the week in Psychiatric Times.
Opioid Use Disorder Research Roundup: April 19, 2024
What is new in research on opioid use disorder?
NeuroStar TMS and the Future of MDD Treatment for Adolescents
What does the recent FDA clearance of this treatment for adolescents mean for the future of MDD treatment?
Tris Digital Health Forms, Will Focus on Digital Diagnostic Platform for ADHD
Tris Pharma has formed the organization along with a licensing agreement with Braingaze for development, distribution of the technology.
Publication of Phase 1 Results Announced for BPL-003
Study results suggest the potential for a scalable, single-dose treatment approach.
SUDs in Women and the Importance of Tailored Treatment Approaches
What are the most effective approaches to SUD treatment in this unique patient population?
Telehealth for the Treatment of OUD in Pregnant Patients
How can telehealth aid in the treatment of opioid use disorders in this patient population?
In Conversation With a Sigourney Award Winner: The Intersection Between Psychoanalytic Thought and Social Anthropology
Rosine Perelberg, PhD, discusses psychoanalytic thought, social anthropology, and the future of psychoanalysis.
The Week in Review: April 8-12
From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.
Study Finds That Probiotics, Vitamin D May Enhance Cognitive Function in Schizophrenia
Researchers investigated the effects of this supplementation on cognitive function and disease severity in schizophrenia. Here’s what they found.
Schizophrenia Research Roundup: April 12, 2024
What is new in research on schizophrenia?
Addiction & Substance Use in Psychiatric Times
Take a look back at our recent coverage relating to our April content theme.
The Week in Review: April 1-5
From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.
Alcohol Use Disorder Research Roundup: April 5, 2024
What is new in research on alcohol use disorder?
National Alcohol Screening Day 2024
In honor of this year’s National Alcohol Screening Day, here’s a look back at some recent coverage in Psychiatric Times about the diagnosis, treatment, and management of alcohol misuse.
FDA: Specific Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer Disease Needed for Rolling Review
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.
First Patient Dosed in Phase 2 Clinical Trial of NBI-1070770 for MDD
“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”
FDA Approves Fanapt for Mixed, Manic Episodes Associated With Bipolar I Disorder
The atypical antipsychotic was approved for the acute treatment of schizophrenia in 2009.
Presenting Our April Theme: Addiction and SUDs
Write to us now to be part of our series focused on addiction and substance use disorders this month.
From the Pages of Psychiatric Times: March 2024
The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.
The Week in Review: March 25-29
From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.
An Update on Bipolar I Disorder
Our Mood Disorders Section Editor discusses the disorder in honor of World Bipolar Day.
Psychiatry in the News: March 2024
Here are some updates from the world of psychiatry throughout the month of March.
Bipolar Disorder Research Roundup: March 29, 2024
What is new in research on bipolar disorder?
Recap: Mood Disorders 2024
Here’s a look back at selections from our March content series on mood disorders.
Neuromodulation for Depressive Disorders: Top 5 Takeaways
Our March CME reviews the principles and applications of invasive and noninvasive neuromodulation techniques for the treatment of mood disorders. Here are 5 key takeaways.
FDA Clears NeuroStar TMS for Treatment of MDD in Adolescents
This treatment is now the first and only TMS treatment that is FDA-cleared for this patient population.
The Clubhouse Model for Depression and Serious Mental Illnesses
What is the Clubhouse model of psychosocial rehabilitation, and how can it benefit both patients and clinicians alike?
Evidence-Based Novel Therapies for Bipolar Depression: Top 5 Takeaways
Expiring on May 20, 2024, this CME discusses how to apply several novel treatment approaches in the treatment of patients with bipolar depression. Here are 5 key takeaways.
Phase 3 Trial of AXS-12 for Narcolepsy Meets Primary Endpoint
The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo.